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Abstract 
Modulation of energy metabolism is emerging as a key aspect associated with cell fate 
transition. The establishment of a correct metabolic program is particularly relevant for neural 
cells given their high bioenergetic requirements. Accordingly, diseases of the nervous system 
commonly involve mitochondrial impairment. Recent studies in animals and in neural 
derivatives of human pluripotent stem cells (PSCs) highlighted the importance of 
mitochondrial metabolism for neural fate decisions in health and disease. The mitochondria-
based metabolic program of early neurogenesis suggests that PSC-derived neural stem cells 
(NSCs) may be used for modeling neurological disorders. Understanding how metabolic 
programming is orchestrated during neural commitment may provide important information 
for the development of therapies against conditions affecting neural functions, including aging 
and mitochondrial disorders. 
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Within the nervous system, stem cells need to generate both neurons and glia [1–3]. Their 
derivation -collectively defined here as neurogenesis - requires the careful orchestration of 
cell type-specific epigenetic signatures. These signatures may be influenced by the metabolic 
state of the cells, given that metabolites can act as epigenetic regulators [4]. At the same time, 
the transcriptional reorganization associated with neural specification generates distinct 
metabolic programs that may also be cell type-specific and may in turn contribute to the 
correct establishment of the needed cellular identity. 
Here, we discuss recent literature addressing how the metabolic programs of neurons 
and glia are constructed. The works have been conducted both in animals and in neural 
derivatives of human pluripotent stem cells (PSCs). It is important to point out that the 
generation of neural cells in vitro can be influenced by the culture conditions, including 
signaling molecules and oxygen levels [5]. Therefore, the metabolism of in vitro derived 
human neural cells may not necessarily mirror that of the actual neural cells residing in the 
human brain. Nonetheless, the use of human PSC neural derivatives is allowing for the first 
time to investigate the metabolic regulation of human brain cells.  
Some of the recent findings that we will discuss here, generated from in vivo and in 
vitro experiments, have challenged the conventional idea associated with the metabolic 
remodeling of neurogenesis. The picture emerging is that metabolism is more plastic than 
previously expected and that it can be fine-tuned at different levels during neural 
commitment. We also comment on clinically relevant opportunities that are starting to be 
translated from these basic studies. We believe that this renewed interest in the metabolic 
contribution to neural specification may bring important insights for the study of diseases 
affecting the nervous system, including neurodegeneration and mitochondrial disorders.  
 
 
 
 4 
Glycolytic metabolism and neurogenesis 
The metabolic programs of neurons and glia are considered to be very divergent. 
Neurons are dependent on mitochondrial-based oxidative phosphorylation (OXPHOS) while 
glia rely on glycolysis [6,7]. Both cell types are generated from multipotent neural stem cells 
(NSCs), which appear to share some of the features of glial cells, including the reliance on 
glycolytic metabolism [2,8]. Given that the modulation of metabolism may be instrumental 
during neural commitment [9], it becomes critical to investigate how the cell type-specific 
metabolic programs are regulated.  
The glycolytic nature of NSCs is usually explained by the fact that glycolysis is the 
preferred metabolic route of stemness [10]. Accordingly, PSC-derived neural progenitor cells 
(NPCs) have been found to depend on glycolytic metabolism [11]. Moreover, metabolic 
profiling of cells exiting pluripotency in vitro indicates that the metabolic switch towards 
OXPHOS does not occur uniformly for all germ layers, as ectodermal lineage and NPC 
induction still require the maintenance of a high glycolytic flux [12]. 
The picture becomes more complicated when we consider the proliferative rate of stem 
cells. In the case of PSCs, for example, the glycolytic metabolism is suggested to be a 
consequence of their elevated level of proliferation [13,14]. Highly proliferative cells like 
cancer cells prefer indeed glycolysis, since it provides the precursor molecules for biomass 
generation via the pentose phosphate pathway (PPP) that emerges from the upstream branches 
of glycolysis [15]. In the case of hematopoietic stem cells (HCS), however, glycolysis is 
considered to be chosen over OXPHOS due to the fact that HSCs do not actively proliferate 
and therefore do not have high bioenergetic needs [16,17]. These findings raise the question 
of why stem cells would prefer glycolysis regardless of their rate of proliferation. The 
relationship between proliferation and stem cell metabolism may be particularly important in 
the context of the nervous system. NSCs in vivo can in fact rapidly divide during development 
but become quiescent in adult age [18].  
 5 
One possibility is that the stem cell reliance on glycolysis is linked to the regulation of 
redox metabolism. The use of glycolysis may reduce the intracellular levels of reactive 
oxygen species (ROS) generated as OXPHOS by-products and at the same time it may 
enhance the production of the antioxidant glutathione through the PPP-mediated generation of 
the NADPH [19]. ROS can also function as second messengers. The regulation of redox 
homeostasis may play a crucial role in the self-renewal of NSCs [20]. The physiological effect 
of ROS may contribute to the induction of neurogenesis in vivo [21]. Intermittent generation 
of ROS in proliferative NPCs in the developing cortex in vivo negatively influences their rate 
of proliferation [22], suggesting that low ROS levels are indeed beneficial for NPCs. Recent 
in vivo findings demonstrated that mouse embryonic NSCs exhibit reduced amount of ROS, 
while committed NPCs increase ROS production to promote differentiation [23]. NPC 
differentiation in vivo may be induced following a transcriptional program activated by the 
nuclear factor erythroid 2-related factor 2 (NRF2) [23]. NRF2 is indeed known to stimulate 
the expression of genes involved in redox signaling, thereby supporting neuronal 
differentiation by protecting against toxic insults [24]. 
The induction of glycolysis in NSCs might also be influenced by the level of oxygen 
and by the activation of hypoxia inducible factors (HIFs) [25]. This was found to be the case 
in the context of PSCs [26,27]. The oxygen sensing response can in fact be controlled by 
cellular ROS rather than by OXPHOS metabolism per se [28]. Nevertheless, the glycolytic 
metabolic state of ex vivo mouse NSCs has been found to be not dependent on HIFs [29]. At 
the same time, HIFs may be important in the in vitro derivation of NPCs from human PSCs, 
as the level of oxygen has been suggested to modulate whether NPCs can differentiate more 
efficiently into neurons or glia [30]. Therefore, the importance of HIF-mediated response in 
neurogenesis requires further investigations. 
Another possibility for explaining the reliance on glycolysis of NSCs and glia and the 
reliance on OXPHOS in the case of neurons may be that these metabolic programs may 
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contribute to the epigenetic regulation of the respective cell fate. The process of establishing a 
cell fate identity requires a complex integration between environmental cues and 
transcriptional states [13]. In this scenario, cellular metabolism may represent the mechanism 
through which a cell responds to both exogenous stimuli and gene expression programs [4]. 
Within the complex regulation of epigenetics during neural cell commitment [31], however, 
the importance of metabolism still remains largely unexplored. 
 
Mitochondrial metabolism and dynamics during neurogenesis 
An important aspect that has been recently challenged of the classical view of 
metabolism in neurogenesis relates to the time point in which the oxidative metabolic 
program is activated and to the respective morphology of mitochondria.  
As mentioned above, the NSC state is believed to be linked with glycolytic metabolism 
coupled to non-fused mitochondrial morphology, which is considered typical for glycolytic 
stem cells [32]. In the neural lineage, OXPHOS metabolism is usually associated only with 
differentiated neurons [7,33], which exhibit a tubular mitochondrial network. This has been 
confirmed in several recent works investigating the mitochondrial state of neurons derived in 
vitro from human PSCs [11,34,35]. Proteomics analysis further underscored the increase of 
OXPHOS-related proteins in differentiating neurons both in vitro and in vivo [36,37].  
In contrast to the assumptions about the mitochondrial state of NSCs, recent findings 
demonstrated that mouse embryonic NSCs exhibit elongated mitochondria in vivo while 
remaining glycolytic [23]. At the same time, proliferative NPCs in vivo displayed non-fused 
fragmented mitochondria [23]. Mouse adult NSCs in vivo have been found to possess 
mitochondria with a mixed globular and tubular shape that becomes consistently more 
elongated in proliferative intermediate progenitor cells (IPCs) [38]. Consequently, single cell 
transcriptomics identified the up-regulation of OXPHOS components and the down-regulation 
of glycolytic enzymes during the transition between NSCs and IPCs in vivo [38].  
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In agreement with a potential activation of the oxidative metabolic program in early 
neural fate commitment, NPCs derived in vitro from human PSCs have been found to display 
tubular mitochondria and a reduction of glycolytic metabolism when compared to PSCs [39]. 
The apparent disagreement of these latter findings with other published works on PSC-
derived NPCs [11,12], may perhaps be explained by the type of signaling molecules used for 
the derivation of NPCs in vitro. Glycolytic NPCs were cultivated using basal FGF [11], which 
may be per se associated with enhanced glycolysis [40]. Conversely, oxidative NPCs were 
grown with LIF [39], which promotes mitochondrial metabolism [41]. Collectively, these data 
indicate that activation of the OXPHOS program during neurogenesis may occur earlier than 
expected [42] and that it may be influenced by signaling and environmental cues (Figure 1).  
This novel concept of how metabolic programs are orchestrated during neural 
commitment underscores the metabolic plasticity associated with the cell fate transitions. In 
this emerging picture, it will be relevant to dissect the state of mitochondrial metabolism and 
dynamics of glia cells. Astrocytes are considered to be dependent on glycolytic metabolism, 
as they can produce glycolysis-derived lactate that is then secreted and used to fuel neurons 
[6]. Oligodendrocytes also rely on glycolysis [43], further supporting the metabolic 
compartmentalization of the central nervous system. Nonetheless, the lactate produced by 
astrocytes and oligodendrocytes can also be obtained from pyruvate generated from malate 
coming from the mitochondrial tricarboxylic acid (TCA) cycle [44]. Hence, mitochondrial 
metabolism might also be potentially relevant for glial cells. Accordingly, glioblastoma cells 
forced to increase OXPHOS and mitochondrial biogenesis efficiently differentiate into 
astrocytes [45].  
Understanding the relevance of mitochondria for glia cells might be important for 
facilitating the reprogramming of astrocytes into neurons [46], given that metabolism 
represents a critical roadblock in this process [47]. The investigation of astrocytic 
mitochondria may also provide essential clues to explain the phenomenon of mitochondrial 
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transfer between astrocytes and neurons that has been reported to occur in vivo in mice 
following ischemic insults [48]. 
 
Targeting mitochondria for improving neurogenesis in neurological diseases 
Mitochondrial defects are a known pathogenetic mechanism involved in conditions 
causing neurological impairment, including aging-associated neurodegeneration [49]. At the 
same time, mitochondrial disorders due to OXPHOS mutations usually cause symptoms at the 
level of the nervous system [50]. The findings discussed above open new avenues in our 
understanding of these human diseases and in the development of therapies. 
If OXPHOS metabolism is relevant not only for fully differentiated neurons but also for 
proliferative neural precursors, diseases impairing mitochondria could also affect 
neurogenesis and targeting mitochondrial function may represent a strategy for improving 
neural defects [51]. Accordingly, piracetam-mediated activation of mitochondrial respiration 
promoted neurogenesis in vivo in aged mice [38]. Furthermore, mitochondrial dysfunctions 
due to PINK1 deficiency caused defective neurogenesis in a mouse model of Parkinson’s 
disease [52]. Enhanced mitochondrial function upon modulation of microRNA-210 led to 
improved NSC proliferation and differentiation in vitro following inflammatory insults [53].  
The findings also suggest that iPSC-derived NPCs may represent a viable model for 
investigating neurological diseases. NPCs from patients affected by schizophrenia have been 
found to exhibit disease-associated phenotypes [54]. The use of NPCs may particularly be 
important for mitochondrial disorders that are caused by mutations in the mitochondrial DNA 
(mtDNA) and for which there is a lack of viable modeling systems [55]. iPSC-derived NPCs 
from patients affected by Leigh syndrome carrying a mtDNA mutation in the gene MT-ATP6 
have been used for the establishment of a drug discovery platform [39]. Leigh syndrome 
NPCs displayed a defect in calcium homeostasis that was observed in neurons but not in other 
peripheral cells [39]. The observed NPC defects might imply that Leigh syndrome also affects 
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neurogenesis. Interestingly, hypoxia stimulation was recently shown to significantly improve 
the life-span of a mouse model of Leigh syndrome [56]. The mechanisms underlying the 
beneficial effect of hypoxia in the Leigh syndrome mice remain unclear. However, given the 
above-mentioned importance of redox metabolism and HIFs signaling for NSCs and their 
glycolytic state, it is perhaps possible that hypoxic exposure may be beneficial to Leigh 
syndrome mice because it promotes NSC proliferation and neurogenesis. 
In conclusion, the recent data addressing how the metabolic programs of neural cells are 
established in vitro and in vivo is challenging the traditional view of neurogenesis and is 
opening new ways to approach and cure disorders of the nervous system. A deeper 
understanding of the metabolic programming occurring upon neural fate commitment will 
shed new lights on how brain cells are generated and how we can develop strategies to restore 
their function during disease states.  
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Figure legends 
Figure 1. Mitochondrial metabolism and dynamics during neurogenesis. Cartoon 
depicting the orchestration of metabolic programs and mitochondrial states during the 
generation of neurons and glia based on the studies conducted in mouse in vivo and in PSC 
derivatives in vitro. The color code refers to the energy metabolism of the cells: blue for 
glycolysis (in PSCs, NSCs, astrocytes, oligodendrocytes, and PSC-derived NPCs grown with 
basal FGF), light red for intermediate OXPHOS metabolism (in proliferative IPCs and PSC-
derived NPCs cultured with LIF), and dark red for marked OXPHOS metabolism (in mature 
neurons). The grey arrows above the cells refer to the reported proliferative rates. The 
morphology of mitochondria is simplified and shown as non-fused roundish organelles with 
sparse cristae (in PSC, glycolytic NPCs, and glial progenitors), as partly elongated organelles 
(in NSCs, IPCs, oxidative NPCs, and astrocytes and oligodendrocytes), and as strongly 
elongated organelles (in mature neurons). Abbreviations: PSC= pluripotent stem cell; NSC= 
neural stem cell; NPC= neural progenitor cell; IPC= intermediate progenitor cell; OXPHOS= 
oxidative phosphorylation. 

